Mesenchymal stem cells (MSCs) can be widely isolated from various tissues including bone
marrow, umbilical cord, and adipose tissue, with the potential for self-renewal and …

Many patients with interstitial lung disease (ILD) develop pulmonary fibrosis, which can lead
to reduced quality of life and early mortality. Patients with fibrotic ILD often have …

Interstitial lung diseases (ILDs) other than idiopathic pulmonary fibrosis (IPF) have an array
of immunomodulatory treatment options compared with IPF, due to their inflammatory …

Pirfenidone (PFD) is a non-peptide synthetic chemical that inhibits the production of
transforming growth factor-beta 1 (TGF-β1), tumor necrosis factor-alpha (TNF-α), platelet …

Similarly to idiopathic pulmonary fibrosis (IPF), other interstitial lung diseases can develop
progressive pulmonary fibrosis (PPF) characterized by declining lung function, a poor …

Background: The American Thoracic Society, European Respiratory Society, Japanese
Respiratory Society, and Asociación Latinoamericana del Tórax convened to update clinical …

Background Pulmonary fibrosis is the deadliest manifestation of connective tissue disease
(CTD). Iguratimod (IGU) is a new drug that is used for controlling CTD. Clinical studies have …

Background: The American Thoracic Society, European Respiratory Society, Japanese
Respiratory Society, and Asociación Latinoamericana del Tórax convened to update clinical …

Connective tissue disease-associated interstitial lung disease (CTD-ILD) is a collection of
systemic autoimmune disorders resulting in lung interstitial abnormalities or lung fibrosis …

Background Interstitial lung disease (ILD) is associated with substantial morbidity and
mortality, which is one of the key systematic manifestations of connective tissue disease …